The Joint Corp. delivered a solid third quarter in 2025, with revenue increasing by 6% to $13.4 million and consolidated net income reaching $855,000, a significant improvement from a net loss in the prior year. The company also reported a positive consolidated EPS of $0.06 per diluted share and a substantial increase in Adjusted EBITDA from consolidated operations.

The Joint Corp. demonstrated progress in its multi-year strategy during Q2 2025, with a 5% increase in revenue to $13.3 million and a substantial turnaround in consolidated net income to $93,000 from a $3.6 million loss in Q2 2024. The company continued its transition to a pure-play franchisor model, with franchised clinics now representing 92% of its portfolio.

The Joint Corp. reported a 7% increase in revenue from continuing operations to $13.1 million in Q1 2025, alongside a 5% rise in system-wide sales to $132.6 million, demonstrating economic resilience despite a net loss from continuing operations of $506,000.

The Joint Corp. posted a 14% revenue increase in Q4 2024, reaching $14.4 million. System-wide sales grew by 9%, while comp sales rose 6%. The company reported net income of $986,000, a significant turnaround from the prior year’s net loss. The business continued to focus on franchising and operational efficiency, leading to improved Adjusted EBITDA of $2.1 million.

The Joint Corp. reported a 2% increase in revenue to $30.2 million, but net loss was $3.2 million, including $3.8 million in loss on disposition or impairment. System-wide sales increased 8% to $129.3 million.

The Joint Corp. reported a 3% increase in revenue to $30.3 million for Q2 2024. System-wide sales increased by 8% to $129.6 million, and system-wide comp sales grew by 2%. The company reported a net loss of $3.6 million, including $1.5 million in litigation expense and $1.4 million in loss on disposition or impairment. Adjusted EBITDA was $2.1 million.

The Joint Corp. reported a 5% increase in revenue to $29.7 million and operating income of $1.1 million. Net income was $947,000, compared to $2.3 million in the previous year, which included a $3.9 million employee retention credit. System-wide sales increased by 9% to $126.3 million, and system-wide comp sales grew by 3%.

The Joint Corp. reported a revenue of $30.6 million for Q4 2023, compared to $27.7 million in Q4 2022. The company experienced a net loss of $11.0 million, or $0.75 per basic share, compared to net income of $763,000, or $0.05 per diluted share, in the fourth quarter of 2022. Adjusted EBITDA remained consistent at $4.0 million for both Q4 2023 and Q4 2022.

The Joint Corp. reported revenue of $29.5 million for Q3 2023, compared to $26.5 million in Q3 2022. The company experienced an operating loss of $898,000, a net loss of $716,000, or $0.05 per share, and an adjusted EBITDA of $2.9 million.

The Joint Corp. reported preliminary Q2 2023 revenue of $29.3 million, an 18% increase compared to Q2 2022. Preliminary Adjusted EBITDA was $3.2 million, a 23% increase compared to Q2 2022. The company is evaluating programs to cull approximately 10% of the corporate portfolio to improve profitability.

The Joint Corp. reported a 27% increase in revenue and a net income of $2.3 million for Q1 2023, driven by a greater number of clinics and organic growth.

The Joint Corp. reported a revenue of $27.8 million for Q4 2022, a 26% increase compared to Q4 2021. The company's operating income increased to $1.3 million, and net income was $547,000, or $0.04 per diluted share. The company increased clinic count to 838 at year-end 2022, including 126 company-owned or managed clinics.

The Joint Corp. reported a 27% increase in revenue to $26.6 million and system-wide sales grew 18% to $110.4 million. The company opened 38 new clinics and surpassed the 800 clinic milestone, closing the quarter with 805 clinics.

The Joint Corp. reported revenue of $25.1 million, a net income of $345,000, and earnings per diluted share of $0.02 for the second quarter of 2022. The company opened 34 clinics, bringing the total to 769, and sold 24 franchise licenses.

The Joint Corp. reported a revenue of $22.4 million, a net loss of $206,000, or $0.01 per share, and an adjusted EBITDA of $1.8 million. The company opened 31 clinics, including 27 franchised, and achieved a milestone of 100 corporate portfolio clinics, bringing total clinics to 736.

The Joint Corp. reported a revenue of $22.4 million for Q4 2021, compared to $17.0 million in Q4 2020. Net income was $224,000, or $0.01 per diluted share, compared to $10.6 million, or $0.72 per diluted share, in the fourth quarter of 2020.

The Joint Corp. reported strong financial results for the third quarter of 2021, with significant growth in revenue, system-wide sales, and franchise licenses sold. The company's expansion strategy and increasing market share in the chiropractic industry contributed to the positive performance.

The Joint Corp. reported record second-quarter financial results, with significant growth in revenue, system-wide sales, and operating income. The company also raised all elements of its guidance for the year.

The Joint Corp. reported a 29% increase in revenue, a 28% increase in system-wide sales, and a 21% increase in system-wide comp sales compared to Q1 2020. The company's operating income increased by 162%, and adjusted EBITDA increased by 108%.

The Joint Corp. reported a 23% increase in quarterly revenue and a 21% increase in annual revenue. The company also reported a record annual operating income of $5.5 million, up 61% compared to 2019, and a record adjusted EBITDA of $9.1 million, up 47% compared to 2019.

The Joint Corp. reported a strong third quarter with a 21% increase in revenue compared to Q3 2019, reaching $15.4 million. The company also achieved a record net income of $1.6 million, up 160% from the previous year, and a record adjusted EBITDA of $2.6 million, an 84% increase.

The Joint Corp. reported a revenue increase of 13% compared to Q2 2019, driven by a greater number of clinics. The company's net income was $116,000, or $0.01 per diluted share.

The Joint Corp. reported a revenue of $13.6 million, a net income of $815,000, and system-wide sales growth of 24%. The company opened 17 clinics and sold 24 franchise licenses during the quarter.

The Joint Corp. reported a revenue of $13.9 million and net income of $1.3 million for the fourth quarter of 2019. The company's Adjusted EBITDA improved to $2.1 million. They also increased franchise licenses sales to 126.